Abstract
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
Highlights
Cabazitaxel is a novel taxane and an effective second-line agent in patients with metastatic castrationresistant prostate cancer refractory to a docetaxel-containing regimen
In March 2010, his prostatespecific antigen (PSA) level increased to 7.5 ng/mL (Fig. 1) and radiologic evaluation showed a stable bone defect affecting the right side of L4 vertebral body, with a soft tissue mass exhibiting mild increased uptake, but there were no signs suggesting local recurrence in the prostatic bed
In 2010, the U.S Food and Drug Administration (FDA) approved cabazitaxel for use in combination with prednisone for treatment of patients with mHRPC previously treated with a docetaxel-containing regimen
Summary
Cabazitaxel is a novel taxane and an effective second-line agent in patients with metastatic castrationresistant prostate cancer (mCRPC) refractory to a docetaxel-containing regimen. We report a patient with mCRPC who received prior treatment with docetaxel and was given cabazitaxel as salvage therapy. Treatment response was monitored by prostatespecific antigen (PSA) doubling timeand PSA absolute value
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
